The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Pharmacokinetic issues for antibiotics in the critically ill patient
Abstract
OBJECTIVE: To discuss the altered pharmacokinetic properties of selected antibiotics in critically ill patients and to develop basic dose adjustment principles for this patient population. DATA SOURCES: PubMed, EMBASE, and the Cochrane-Controlled Trial Register. STUDY SELECTION: Relevant papers that reported pharmacokinetics of selected antibiotic classes in critically ill patients and antibiotic pharmacodynamic properties were reviewed. Antibiotics and/or antibiotic classes reviewed included aminoglycosides, beta-lactams (including carbapenems), glycopeptides, fluoroquinolones, tigecycline, linezolid, lincosamides, and colistin. DATA SYNTHESIS: Antibiotics can be broadly categorized according to their solubility characteristics which can, in turn, help describe possible altered pharmacokinetics that can be caused by the pathophysiological changes common to critical illness. Hydrophilic antibiotics (e.g., aminoglycosides, beta-lactams, glycopeptides, and colistin) are mostly affected with the pathphysiological changes observed in critically ill patients with increased volumes of distribution and altered drug clearance (related to changes in creatinine clearance). Lipophilic antibiotics (e.g., fluoroquinolones, macrolides, tigecycline, and lincosamides) have lesser volume of distribution alterations, but may develop altered drug clearances. Using antibiotic pharmacodynamic bacterial kill characteristics, altered dosing regimens can be devised that also account for such pharmacokinetic changes. CONCLUSIONS: Knowledge of antibiotic pharmacodynamic properties and the potential altered antibiotic pharmacokinetics in critically ill patients can allow the intensivist to develop individualized dosing regimens. Specifically, for renally cleared drugs, measured creatinine clearance can be used to drive many dose adjustments. Maximizing clinical outcomes and minimizing antibiotic resistance using individualized doses may be best achieved with therapeutic drug monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“In vivo animal experiments have demonstrated that -lactams have a slow continuous kill characteristic that is almost entirely related to T MIC (71).”
BackgroundClinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Pathogenetic Mechanisms of Septic Shock
Epstein, F. H., & Parrillo, J. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282008 · Cited by 1,548 · cited 1×
“It is, therefore, not surprising that critically ill patients often have higher than normal cardiac indices (13, 22).”
BackgroundColistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Parrillo, J. E., Parker, M. M., Natanson, C., Suffredini, A. F., Danner, R. L., Cunnion, R. E., & Ognibene, F. P. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-3-227 · Cited by 1,179
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Calandra, T., & Cohen, J. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000168253.91200.83 · Cited by 839
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Garnacho-Montero, J., Garcia-Garmendia, J. L., Barrero-Almodovar, A., Jimenez-Jimenez, F. J., Perez-Paredes, C., & Ortiz-Leyba, C. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000098031.24329.10 · Cited by 718
Harbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Lodise, T. P., Lomaestro, B., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510590 · Cited by 527
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
Blaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome
Marshall, J. C. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107001-00032 · Cited by 457
Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E., & Testa, R. T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.738 · Cited by 415
Wysocki, M., Delatour, F., Faurisson, F., Rauss, A., Pean, Y., Misset, B., Thomas, F., Timsit, J.-F., Similowski, T., Mentec, H., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2460-2467.2001 · Cited by 385
Once versus thrice daily gentamicin in patients with serious infections
Prins, J. M., Buller, H. R., Speelman, P., Kuijper, E. J., & Tange, R. A. (1993) · The Lancet · doi:10.1016/0140-6736(93)90137-6 · Cited by 350
Antibiotic resistance—What’s dosing got to do with it?
Roberts, J. A., Kruger, P., Paterson, D. L., & Lipman, J. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318180fe62 · Cited by 339
Self-citationPharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects
Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., & Troy, S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.220-229.2005 · Cited by 333
Craig, W. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321854 · Cited by 318
Kinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
MacGowan, A. P. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg248 · Cited by 299
Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy
Trotman, R. L., Williamson, J. C., Shoemaker, D. M., & Salzer, W. L. (2005) · Clinical Infectious Diseases · doi:10.1086/444500 · Cited by 292
Joukhadar, C., Frossard, M., Mayer, B. X., Brunner, M., Klein, N., Siostrzonek, P., Eichler, H. G., & Müller, M. (2001) · Critical Care Medicine · doi:10.1097/00003246-200102000-00030 · Cited by 279
In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)
Andes, D., van Ogtrop, M. L., Peng, J., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3484-3489.2002 · Cited by 278
Mouton, J. W., & den Hollander, J. G. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.5.931 · Cited by 275
Chastre, J., Wunderink, R., Prokocimer, P., Lee, M., Kaniga, K., & Friedland, I. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181691b99 · Cited by 237
A Meta-Analysis of Extended-Interval Dosing Versus Multiple Daily Dosing of Aminoglycosides
Bailey, T. C., Little, J. R., Littenberg, B., Reichley, R. M., & Dunagan, W. C. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.786 · Cited by 222
Ali, M. Z., & Goetz, M. B. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.796 · Cited by 220
Hoste, E. A. J., Damen, J., Vanholder, R. C., Lameire, N. H., Delanghe, J. R., Van den Hauwe, K., & Colardyn, F. A. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh707 · Cited by 210
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3624-3630.2005 · Cited by 204
Safety and tolerability of linezolid
French, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg253 · Cited by 203
The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients
Joynt, G. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.421 · Cited by 200
Tam, V. H., Schilling, A. N., Neshat, S., Poole, K., Melnick, D. A., & Coyle, E. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4920-4927.2005 · Cited by 196
Markou, N., Markantonis, S. L., Dimitrakis, E., Panidis, D., Boutzouka, E., Karatzas, S., Rafailidis, P., Apostolakos, H., & Baltopoulos, G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.01.015 · Cited by 191
Whole-Body Inflammation in Trauma Patients: An Autopsy Study
Nuytinck, H. K. S. (1988) · Archives of Surgery · doi:10.1001/archsurg.1988.01400360089016 · Cited by 190
The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline
Meagher, A. K., Ambrose, P. G., Grasela, T. H., & Ellis‐Grosse, E. J. (2005) · Clinical Infectious Diseases · doi:10.1086/431674 · Cited by 188
Roberts, J. A., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181968e44 · Cited by 183
Self-citationLorente, L., Lorenzo, L., Martín, M. M., Jiménez, A., & Mora, M. L. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g467 · Cited by 181
Mouton, J. W., & Vinks, A. A. T. M. M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00005 · Cited by 177
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients
Li, C., Kuti, J. L., Nightingale, C. H., & Nicolau, D. P. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291035 · Cited by 171
van der Poll, T. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00093-7 · Cited by 167
Boselli, E., Breilh, D., Rimmelé, T., Djabarouti, S., Toutain, J., Chassard, D., Saux, M.-C., & Allaouchiche, B. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000168206.59873.80 · Cited by 164
Daikos, G. L., Lolans, V. T., & Jackson, G. G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.117 · Cited by 163
Vancomycin dosing in morbidly obese patients
Bauer, L. A., Black, D. J., & Lill, J. S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050524 · Cited by 162
Experience with a once-daily dosing program of aminoglycosides in critically ill patients
Buijk, S. L. C. E., Mouton, J. W., Gyssens, I. C., Verbrugh, H. A., & Bruining, H. A. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1313-7 · Cited by 162
Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
Nakashima, M., Uematsu, T., Kosuge, K., Kusajima, H., Ooie, T., Masuda, Y., Ishida, R., & Uchida, H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2635 · Cited by 160
Therapeutic Intervention and Targets for Sepsis
Rice, T. W., & Bernard, G. R. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104356 · Cited by 158
Vogelman, B., & Craig, W. A. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.suppl_a.37 · Cited by 153
Jaruratanasirikul, S., Sriwiriyajan, S., & Punyo, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1337-1339.2005 · Cited by 149
Zhou, J., Dong, Y., Zhao, X., Lee, S., Amin, A. G., Ramaswamy, S. V., Domagala, J. M., Musser, J. M., & Drlica, K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315708 · Cited by 148
Aminoglycoside Volume of Distribution and Illness Severity in Critically Ill Septic Patients
Marik, P. E. (1993) · Anaesthesia and Intensive Care · doi:10.1177/0310057x9302100206 · Cited by 145
Herrera-Gutiérrez, M. E., Seller-Pérez, G., Banderas-Bravo, E., Munoz-Bono, J., Lebrón-Gallardo, M., & Fernández-Ortega, J. F. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0745-5 · Cited by 142
Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides*
Rello, J., Solé‐Violán, J., Borges-Sa, M., Garnacho‐Montero, J., Muñoz, E., Sirgo, G., Olona, M., & Dı́az, E. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000178180.61305.1d · Cited by 141
Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent
Meagher, A. K., Ambrose, P. G., Grasela, T. H., & Ellis‐Grosse, E. J. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.05.006 · Cited by 138
Roberts, J. A., Boots, R. J., Rickard, C. M., Thomas, P., Quinn, J., Roberts, D. M., Richards, B., & Lipman, J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl478 · Cited by 138
Self-citationRyan, D. M. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.suppl_d.1 · Cited by 133
Gentamicin volume of distribution in critically ill septic patients
Triginer, C., Izquierdo, I., Fernández, R., Rello, J., Torrent-Farnell, J., Benito, S., & Net, A. (1990) · Intensive Care Medicine · doi:10.1007/bf01706354 · Cited by 128
Löwdin, E., Odenholt, I., & Cars, O. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2739 · Cited by 126
Marik, P. E., Lipman, J., Kobilski, S., & Scribante, J. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.5.753 · Cited by 124
Self-citationBuerger, C., Plock, N., Dehghanyar, P., Joukhadar, C., & Kloft, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01468-05 · Cited by 122
Intermittent and continuous ceftazidime infusion for critically ill trauma patients
Hanes, S. D., Wood, G. C., Herring, V. L., Croce, M. A., Fabian, T. C., Pritchard, E., & Boucher, B. A. (2000) · The American Journal of Surgery · doi:10.1016/s0002-9610(00)00388-3 · Cited by 119
Buijk, S. L. C. E., Gyssens, I. C., Mouton, J. W., Vliet, A. V., Verbrugh, H. A., & Bruining, H. A. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.121 · Cited by 119
Knudsen, J. D., Fuursted, K., Raber, S. R., Espersen, F., & Frimodt‐Møller, N. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1247-1254.2000 · Cited by 115
Larsson, A. J., Walker, K. J., Raddatz, J. K., & Rotschafer, J. C. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.4.589 · Cited by 115
Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling
Nicolau, D. P. (2003) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-003-0279-x · Cited by 114
Angus, B., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., & White, N. J. (2000) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2000.00179.x · Cited by 114
Lipman, J., Wallis, S. C., & Rickard, C. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.10.2559 · Cited by 114
Self-citationPharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
Roos, J. F., Bulitta, J. B., Lipman, J., & Kirkpatrick, C. M. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl349 · Cited by 108
Self-citationPharmacodynamics, Pharmacokinetics, and Therapeutic Drug Monitoring of Glycopeptides
MacGowan, A. P. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199810000-00005 · Cited by 108
Continuous infusion ceftazidime in intensive care: a randomized controlled trial
Lipman, J., Gomersall, C. D., Gin, T., Joynt, G. M., & Young, R. J. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.2.309 · Cited by 107
Self-citationPopulation pharmacokinetic parameters of vancomycin in critically ill patients
Llopis-Salvia, P., & Jiménez-Torres, N. V. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00762.x · Cited by 105
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen
Georges, B., Conil, J., Cougot, P., Decun, J. F., Archambaud, M., Seguin, T., Chabanon, G., Virenque, C., Houin, G., & Saivin, S. (2005) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp43360 · Cited by 104
Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients
Kitzes‐Cohen, R., Farin, D., Piva, G., & Myttenaere-Bursztein, S. A. D. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00474-5 · Cited by 104
Schentag, J. J. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.6.426 · Cited by 103
Cardiac dysfunction in sepsis: new theories and clinical implications
Grocott-Mason, R. M., & Shah, A. M. (1998) · Intensive Care Medicine · doi:10.1007/s001340050570 · Cited by 103
DEGATTA, M., Calvo, M. V. M., Hernández‐Rivas, J. M., Caballero, D. M., Miguel, J. F. S., & Domínguez‐Gil, A. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90060-0 · Cited by 102
Pea, F., Porreca, L., Baraldo, M., & Furlanut, M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.3.329 · Cited by 100
Generalized vascular permeability and pulmonary function in patients following serious trauma
Gosling, P., Sanghera, K., & Dickson, G. (1994) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-199404000-00002 · Cited by 97 · cited 1×
“This capillary leak syndrome results in fluid shifts from the intravascular compartment to the interstitial space (15, 16).”
BackgroundBarbot, A., Venisse, N., Rayeh, F., Bouquet, S., Debaene, B., & Mimoz, O. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-1859-z · Cited by 97
Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance
Macias, W. L., Mueller, B. A., & Scarim, S. K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.208 · Cited by 93
Pharmacokinetic Evaluation of Meropenem and Imipenem in Critically Ill Patients with Sepsis
Novelli, A., Adembri, C., Livi, P., Fallani, S., Mazzei, T., & Gaudio, A. R. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544050-00007 · Cited by 93
Henderson-Begg, S. K., Livermore, D. M., & Hall, L. M. C. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl064 · Cited by 91
Chien, S., Chow, A. T., Natarajan, J., Williams, R. R., Wong, F. A., Rogge, M. C., & Nayak, R. K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1562 · Cited by 87
Cefepime Versus Cefpirome: The Importance of Creatinine Clearance
Lipman, J., Wallis, S. C., & Boots, R. J. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000077077.54084.b0 · Cited by 85
Self-citationLomaestro, B. M., & Drusano, G. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.461-463.2005 · Cited by 82
Altered Pharmacokinetics of Ceftazidime in Critically Ill Patients
Gómez, C. M., Cordingly, J. J., & Palazzo, M. G. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1798 · Cited by 81
Boselli, E., Breilh, D., Cannesson, M. P., Xuereb, F., Rimmele, T. R., CHASSARD, D., Saux, M., & Allaouchiche, B. (2004) · Intensive Care Medicine · doi:10.1007/s00134-004-2222-8 · Cited by 77
Pharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients
Sauermann, R., Delle‐Karth, G., Marsik, C. L., Steiner, I. M., Zeitlinger, M. A., Mayer‐Helm, B., Georgopoulos, A. P., Müller, M., & Joukhadar, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.650-655.2005 · Cited by 71
Roosendaal, R., Bakker‐Woudenberg, I. A. J. M., Raffe, M. V. D. B.-V., Berg, J., & MICHEL, M. F. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963774 · Cited by 70
The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock
Giantomasso, D. D., Bellomo, R., & May, C. N. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2580-x · Cited by 70
Lipman, J., Wallis, S. C., Rickard, C. M., & Fraenkel, D. J. (2001) · Intensive Care Medicine · doi:10.1007/s001340000741 · Cited by 69
Self-citationBurgess, D. S., & Waldrep, T. W. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80021-2 · Cited by 66
Altered Aminoglycoside Pharmacokinetics in the Critically Ill
Beckhouse, M. J., Whyte, I. M., Byth, P. L., Napier, J. C., & Smith, A. J. (1988) · Anaesthesia and Intensive Care · doi:10.1177/0310057x8801600406 · Cited by 64
Bacteremic sepsis in intensive care: Temporal trends in incidence, organ dysfunction, and prognosis
Hugonnet, S., Harbarth, S., Ferrière, K., Ricou, B., Suter, P. M., & Pittet, D. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000045026.81584.6f · Cited by 63
Pea, F., Qual, E. D., Cusenza, A., Brollo, L., Baldassarre, M., & Furlanut, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342060-00008 · Cited by 61
Goss, T. F., Forrest, A., Nix, D. E., Ballow, C. H., Birmingham, M. C., Cumbo, T. J., & Schentag, J. J. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800707 · Cited by 59
12-Hour versus 24-Hour Creatinine Clearance in Critically Ill Pediatric Patients
Pong, S., Seto, W., Abdolell, M., Trope, A., Wong, K., Herridge, J., Harvey, E. A., & Kavanagh, B. P. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000156225.93691.4f · Cited by 41
Olofsson, S. K., Geli, P., Andersson, D. I., & Cars, O. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5081-5091.2005 · Cited by 37
Application of Basic Pharmacokinetic Concepts to Analysis of Microdialysis Data
Dahyot, C., Marchand, S., Bodin, M., Debeane, B., Mimoz, O., & Couet, W. R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847030-00004 · Cited by 36
Jaruratanasirikul, S., Sriwiriyajan, S., & Ingviya, N. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702171 · Cited by 34
Dose-Ranging Pharmacokinetic Study of Ciprofloxacin after 200-, 300-, and 400-mg Intravenous Doses
Nix, D. E., Spivey, J. M., Norman, A., et al. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202600101 · Cited by 32
Impact of dosage schedule of antibiotics on the treatment of serious infections
Bakker‐Woudenberg, I. A. J. M., & Roosendaal, R. (1990) · Intensive Care Medicine · doi:10.1007/bf01709706 · Cited by 31
Pavie, J., Lefort, A., Ploy, M.-C., Massias, L., Chau, F., Garry, L., Denis, F., & Fantin, B. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.2018-2021.2003 · Cited by 23
A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis
Roberts, J. A., Roberts, M. S., Robertson, T. A., Cross, S. E., & Lipman, J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.09.013 · Cited by 18
Self-citationContinuous infusion of β-lactams in the intensive care unit—Best way to hit the target?*
Roberts, J. A., Paratz, J. D., & Lipman, J. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181704625 · Cited by 16
Self-citationEffect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep
MÖLLER, J. C., GILMAN, J. T., KEARNS, G. L., SUSSMANE, J. B., RASZYNSKI, A., WOLFSDORF, J., & REED, M. D. (1992) · Critical Care Medicine · doi:10.1097/00003246-199210000-00015 · Cited by 15
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Self-citationRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationThe Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance
Kowalska-Krochmal, B., & Dudek-Wicher, R. (2021) · Pathogens · doi:10.3390/pathogens10020165 · Cited by 1,039
Nau, R., Sörgel, F., & Eiffert, H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00007-10 · Cited by 1,026
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539220-000000000-00000 · Cited by 469
“Although these pharmacokinetics cannot be extrapolated to critically ill patients thatmayalsohave physiologically enhancedVd and CL,[2] the data are instructive for describing the effect of hypoalbuminaemia, in the absence of other pathology, on the pharmacokinetics of highly protein-bound antibacterials.”
BackgroundSelf-citation
Metadata
- Authors
- Roberts, J. A., & Lipman, J.
- Venue
- Critical Care Medicine
- Published
- 2009-03
- Volume
- 37
- Issue
- 3
- Pages
- 840-851
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2082321986
- Cited by
- 862
- References
- 118
- FWCI
- 32.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.